Mirxes

The transactions – the majority of which occurred in the second half of 2025 – relate to prepayments in connection with new projects.

Companies & Markets

US$14.8 million in prepayments to vendors behind Mirxes’ missed 2025 results deadline; independent probe set up

The investigation committee will oversee a review of 14 transactions and ‘associated subsequent events’

2026-04-03T02:02:38.000Z

Mirxes specialises in miRNA technology, developing blood-based diagnostic tests for the early detection of cancer and other diseases.

Companies & Markets

Singapore biotech Mirxes misses 2025 results deadline as auditors probe vendor payments

Trading in company’s shares is suspended until its results are published

2026-04-02T09:17:23.000Z

The Hong Kong-listed company did not declare any dividend for the six-month period.

Companies & Markets

A*Star biotech spin-off Mirxes trims losses to US$28.4 million as top line grows

Higher revenue is driven by increased contributions from its early detection and precision multi-omics segment

2025-08-26T06:53:49.000Z

Mirxes says it expects its addition to the index will significantly increase the company’s visibility and trading liquidity.

Companies & Markets

Singapore-headquartered Mirxes to join Alibaba, Tencent on Hang Seng Composite Index

Biotech firm will be part of Hong Kong market benchmark from Sep 8

2025-08-24T09:16:28.000Z

Mirxes intends to use about half of the net proceeds for research and development, regulatory filings and manufacturing and commercialisation of Gastroclear.

Global Enterprise

Singapore biotech firm Mirxes launches IPO in Hong Kong to raise HK$1 billion

Shares are expected to start trading on May 23

2025-05-15T11:53:31.000Z

Mirxes is still considering a secondary listing in Singapore, says CEO Dr Zhou Lihan.

Startups

‘A fighting chance’: Mirxes on why it chose Hong Kong over Singapore for its IPO

Chief executive Dr Zhou Lihan says Hong Kong offered a better valuation and a more savvy investor pool

2023-08-09T21:00:00.000Z

Mirxes co-founder Zhou Lihan says the company hopes to tap Hong Kong and China's healthcare and biotech investor base.

Global Enterprise

Singapore biotech Mirxes files for Hong Kong IPO after raising US$50 million

CANCER diagnostics company Mirxes has applied to Hong Kong’s stock exchange for an initial public offering (IPO), potentially becoming the first company based outside of China and Hong Kong to list un...

2023-07-26T01:00:00.000Z

Latest T-bills Treasury Bills Results & Interest News Latest SSB Singapore Savings Bonds News Latest COE Certificate of Entitlement News

Latest Johor-Singapore SEZ News Latest BTO Build To Order & Sales of Balance News Latest STI Straits Times Index News Latest SGX Dividends, Share Price News Latest Bonds Market News Latest Singapore Stocks To Buy News Latest Singapore Economy News